Intellia Therapeutics, Inc. (NTLA) — Stock Score Summary

Intellia Therapeutics, Inc. (NTLA) has a MoatMap StockRank of 25/100 based on Quality (26/100), Value (36/100), and Momentum (50/100) factor scores. The current signal is SELL. Intellia is a clinical-stage gene editing company. While its CRISPR technology has massive long-term potential, the company is pre-revenue, has high cash burn, and is highly speculative. This violates our Terry Smith and Warren Buffett lenses, which demand high ROIC, positive free cash flow, and predictable earnings.

Intellia Therapeutics, Inc. is a leading clinical-stage genome editing company focused on developing curative medicines using its proprietary CRISPR/Cas9 technology platform. The company is a pioneer in both in vivo and ex vivo gene editing approaches, targeting severe genetic diseases and oncology indications. Its competitive moat stems from its foundational intellectual property and expertise in precision gene editing, positioning it at the forefront of genetic medicine.

Key Financial Metrics

Price$12.89
Market Cap$1.9B
P/E (Forward)-8.02
Price/Book2.86
Return on Equity-56.3%
Return on Invested Capital-59.7%
Debt/Equity12.96
Gross Margin0.0%
Operating Margin-668.1%
Revenue Growth-9.5%
Free Cash Flow$-235M

Intellia Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Intellia Therapeutics, Inc.’s (NTLA) StockRank?
MoatMap’s StockRank for Intellia Therapeutics, Inc. (NTLA) is 25/100, with a Sell signal. It is a composite of Quality (26), Value (36), and Momentum (50) factor ranks across MoatMap’s 19,000+ stock universe.
Does Intellia Therapeutics, Inc. have an economic moat?
Intellia Therapeutics, Inc. (NTLA) has a Quality factor score of 26/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Intellia Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Intellia Therapeutics, Inc. (NTLA) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Intellia Therapeutics, Inc. in?
Intellia Therapeutics, Inc. (NTLA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksNTLA deep dive reportAI ChampionsHow we score stocksSense-check another stock